Nahdi Medical Company

4164

SA15HG521213

Drug Retailers

Market Closed - Saudi Arabian S.E. Other stock markets 08:20:05 2024-05-16 am EDT			5-day change	1st Jan Change
135.4 ^SAR	-1.02%		+1.20%	-1.17%

May. 08	Nahdi Medical Logs Lower Q1 Net Profit; Revenue Rises	MT
Mar. 18	Nahdi Medical Company Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Nahdi Medical Company Reports Earnings Results for the First Quarter Ended March 31, 2023

May 10, 2023

Nahdi Medical Company reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported sales was SAR 2,105.04 million compared to SAR 2,079.49 million a year ago. Net income was SAR 244.34 million compared to SAR 237.51 million a year ago.

Latest news about Nahdi Medical Company

Nahdi Medical Logs Lower Q1 Net Profit; Revenue Rises	May. 08	MT
Nahdi Medical Company Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 18	CI
Nahdi Medical Posts Higher FY23 Net Profit, Revenue	Mar. 18	MT
Nahdi Medical Company Approves Cash Dividend Distribution for the Second Half of 2023	Mar. 17	CI
Nahdi Medical Company Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 10	CI
OptiBiotix says market still "volatile" but partner sales improving	Nov. 01	AN
Saudi Arabia healthcare group Fakeeh Care weighs IPO, appoints HSBC - sources	23-08-27	RE
Nahdi Medical Company Reports Earnings Results for the Second Quarter Ended June 30, 2023	23-08-02	CI
Nahdi Medical Company Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
Nahdi Medical Company Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-19	CI
Nahdi Medical Company Reports Earnings Results for the Third Quarter Ended September 30, 2022	22-11-05	CI
Nahdi Medical Company Reports Earnings Results for the Third Quarter Ended September 30, 2022	22-11-05	CI
OptiBiotix Health gets approval to sell products in Saudi Arabia	22-10-24	AN
OptiBiotix Health Plc Announces Exclusive Distributor Nahdi Medical Co Has Received Approval from the Saudi Food and Drug Authority for GoFigure Shakes and Bars Containing Patented Weight Management Aid Slimbiome	22-10-24	CI
Nahdi Medical Company Announces the Establishment of a New Company, Owned by its Subsidiaries	22-09-29	CI
Certain Ordinary Shares of Nahdi Medical Company are subject to a Lock-Up Agreement Ending on 20-SEP-2022.	22-09-19	CI
Nahdi Medical Company(SASE:4164) added to S&P Global BMI Index	22-09-19	CI
Nahdi Medical Company(SASE:4164) added to S&P Pan Arab Composite	22-09-19	CI
Nahdi Medical Company Announces Distribution of Cash Dividend for First Half of 2022, Payable on August 25, 2022	22-08-09	CI
Nahdi Medical Company(SASE:4164) added to FTSE All-World Index	22-03-30	CI
Nahdi Medical Company has completed an IPO in the amount of SAR 5.109 billion.	22-03-20	CI
Nahdi Medical Company has filed an IPO.	21-12-29	CI
OptiBiotix Health plc Signs Exclusive Sales and Distribution Agreement with Nahdi Medical Co	21-12-15	CI

Chart Nahdi Medical Company

Duration

Period

More charts

Company Profile

Al Nahdi Medical Company SJSC is a Saudi Arabia-based retail pharmacy and healthcare company. The Company is engaged in the wholesale and retail trading of cosmetics, pharmaceutical products, special and healthy foods and medical equipment. The Company operates two operating segments: Front Shop and Pharma. The Company provides medicine, wellness, mom & baby, beauty and other wide-ranging FMCG products. The Company provides omni-health services through its polyclinics, express clinics, telemedicine, labs, and home healthcare. The Company operates approximately 1,150 stores in 144 cities and towns in the Kingdom of Saudi Arabia and the United Arab Emirates. The Companyâs subsidiaries include Al Nahdi Care, Sakhaa Golden Company, and Nahdi Investment Company.

Sector

Drug Retailers

Calendar

2024-05-28 - Shareholders Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Nahdi Medical Company

Trading Rating

Investor Rating

ESG Refinitiv

D-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

135.4 SAR

Average target price

153 SAR

Spread / Average Target

+13.03%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Drug Retailers

	1st Jan change	Capi.
NAHDI MEDICAL COMPANY	-1.17%	4.7B
WALGREENS BOOTS ALLIANCE, INC.	-30.37%	15.68B
JD HEALTH INTERNATIONAL INC.	-22.51%	12.39B
ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED	-22.88%	6.74B
MATSUKIYOCOCOKARA & CO.	-6.01%	6.29B
YIFENG PHARMACY CHAIN CO., LTD.	+11.76%	6.26B
CORPORATIVO FRAGUA, S.A.B. DE C.V.	+70.00%	4.78B
CLICKS GROUP LIMITED	-5.58%	4.03B
DASHENLIN PHARMACEUTICAL GROUP CO., LTD.	-7.87%	3.62B
WELCIA HOLDINGS CO., LTD.	-6.67%	3.06B

Other Drug Retailers